DCMM
ALNY icon

DG Capital Management (Massachusetts)’s Alnylam Pharmaceuticals ALNY Stock Holding History

DG Capital Management (Massachusetts)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,617
Closed -$612K – 57
2015
Q3 		$612K Buy
+7,617
New +$846K 0.41% 60

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

DG Capital Management (Massachusetts)'s ALNY Position: Q4 2015 in Review

DG Capital Management (Massachusetts) sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 7,617 shares — an estimated $612K sold.

DG Capital Management (Massachusetts) first reported a position in ALNY in Q3 2015 and held it in 1 quarter. The position peaked at $612K in Q3 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

  • DG Capital Management (Massachusetts) reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • DG Capital Management (Massachusetts) sold 7,617 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $612K.
  • DG Capital Management (Massachusetts) first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • DG Capital Management (Massachusetts)'s Alnylam Pharmaceuticals position peaked at $612K in Q3 2015.
  • 261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on DG Capital Management (Massachusetts)'s 13F filing for Q4 2015, filed 9 Feb 2016.